HOME>Business Areas>License-in
-
License-in
Leveraging such strong competency in the Korean market, Dong-A has set a new goal to become a global pharmaceutical player and as its first step, we have demerged to the holdings system, of which our parent firm is Dong-A Socio Holdings as of March 2013.
As a sole subsidiary of Dong-A Socio Holdings in prescription drug market, Dong-A ST is dedicated to developing, manufacturing and distributing ethical drugs while harnessing Dong-A’s value and reputation. Along with in-house developed products, Dong-A has attributed its strong growth to licensed-in products from overseas and domestic partners, where we have valued sustainable and long-term relationships. This is exemplified in our strategic partnership with Meiji Seika, which is dated back to 1959, when we established an antibiotics manufacturing plant and of which our values have continued and recently, set up a new alliance in Biosimilar business.
Dong-A ST, equipped with a strong track-record in pharmaceutical development and sales, is actively exploring collaboration opportunities in product licensing and other ways of business alliance. For licensing-in, we are seeking novel and innovative treatments for chronic diseases, especially in CNS, CV and Metabolism as a priority target, while maintaining our excellence in the GI and Urology area. We also have a strong interest in licensing value-added products with improved pharmaco-economic profile compared to existing products. -
Sales
Sales
(Unit : 100milion KRW)
아웃라이센싱 파트너십 표 Product Active ingredient Indication Category Sales 2010 2011 2012 Stillen Eupatilin gastritis In-house 887 881 809 Lipinon Atorvastatin hyperlipidemia generic 410 460 334 Plavitor Clopidogrel antithrombosis generic 437 442 314 Opalmon Limaprost antiplatelet license-in 463 370 244 Growtropin Somatropin growth hormone in-house 173 211 228 Talion Bepotastine antihistaminic license-in 196 200 221 Orodipin Amlodipine high blood pressure generic 289 263 191 Zydena Udenafil erectile dysfunction in-house 200 203 155 Motilitone Corydalinco/Pharbitis functional dyspepsia in-house - 5 145 Glimel Glimepiride diabetes generic 156 154 108 -
Partnership
Unveiled products
아발매제품표 Partner Product Active Ingredient Year Almirall Verrumal Soln. Fluorouracil, Salicylic acid 1991 Optiderm Cream Polidocanol, Urea 1998 Asahi Kasei Pharma Flivas Tab. Naftopidil 2012 Teribone SC inj. Teriparatide 2016 Astellas Pharma Epocelin Inj. Ceftizoxime sodium 1983 Suprax Cap. Cefixime 1989 Powder 1992 Irribow Ramosetron 2010 Dainippon Sumitomo Excegran Zonisamide 1992 LTL Pharma Perdipine LA Cap Nicardipine HCl 1990 iNova Pharmaceuticals Aldara Cream Imiquimod 2002 Nippon Kayaku Bleocin Inj. Bleomycin HCl 1971 Cisplan Inj. Cisplatin 1984 Lastet Inj. Etoposide 1987 Lastet-S Cap. 1991 Ono Pharmaceutical Opalmon Tab. Limaprost 1993 Onon Cap. Pranlukast hydrate 1998 Dry Syr. 2001 Maruishi Foy Inj. Gabexate mesylate 1980 Prostandin Inj. Alprostadil-α-cyclodextrin 1985 Elaspol Sivelestat Na hydrate 2006 Orion Pharma Fareston Tab. Toremifene citrate 1998 Sanofi-Pasteur Vaxiflu Inj. Influenza virus A type,Influenza virus B type 1989 Sigma-Tau Pharmaceuticals Nicetile Tab. Powder Acetyl-L-carnitine HCl 1994 Toyama Chemical Ozex eye drops Tosufloxacin 2010 Crystal Genomics Acelex polmacoxib 2015 Kaken Pharmaceutical Jublia efinaconazole 2017 Co-promotion Celltrion Pharm Edarbi Azilsartan medoxomil 2016 Edarbyclor Azilsartan
medoxomil/Chlorthalidone2016 KyungDong Pharmaceutical Aclova Inj. Acyclovir 2016 Tab. 2017 Cream 2017 * DMARD: Disease modifying anti-rheumatic drug
- Last Update 2013.6-